

CLEVELAND BIOLABS INC  
Form 25  
May 26, 2009  
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION  
Washington, D. C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR  
REGISTRATION UNDER SECTION 12(b) OF THE  
SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 001-32954

Cleveland BioLabs, Inc. – Boston Stock Exchange  
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

73 High Street, Buffalo, New York 14203  
(716) 849-6810

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock, par value \$0.005 per share  
(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

- 17 CFR 240.12d2-2(a)(1)
- 17 CFR 240.12d2-2(a)(2)
- 17 CFR 240.12d2-2(a)(3)
- 17 CFR 240.12d2-2(a)(4)
- Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
- Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements of the Securities Exchange Act of 1934, Cleveland BioLabs, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

May 26, 2009  
Date

By /s/ Michael Fonstein  
Name

Chief Executive Officer  
Title

Edgar Filing: CLEVELAND BIOLABS INC - Form 25

The Nasdaq Stock Market, Inc. previously acquired the Boston Stock Exchange (the “BSE”). Cleveland BioLabs, Inc. was listed on the BSE until September 2007. Currently, our Common Stock is traded on the Nasdaq Capital Market.

1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

SEC 1654 (03-06) Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.